Lara Sullivan - 23 Dec 2024 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Issuer symbol
PYXS
Transactions as of
23 Dec 2024
Net transactions value
$0
Form type
4
Filing time
23 Dec 2024, 16:33:32 UTC
Previous filing
28 Mar 2024
Next filing
02 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $0 +1,135,000 $0.000000 1,135,000 23 Dec 2024 Common Stock 1,135,000 $1.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date.